Triptodur Kit is owned by Arbor Pharms Llc.
Triptodur Kit contains Triptorelin Pamoate.
Triptodur Kit has a total of 1 drug patent out of which 0 drug patents have expired.
Triptodur Kit was authorised for market use on 29 June, 2017.
Triptodur Kit is available in for suspension, extended release;intramuscular dosage forms.
The generics of Triptodur Kit are possible to be released after 30 June, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10166181||ARBOR PHARMS LLC||Slow release pharmaceutical composition made of microgranules|| |
(6 years from now)
|Orphan Drug Exclusivity (ODE)||Jun 29, 2024|
Market Authorisation Date: 29 June, 2017
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic